COVID-19 对血液癌症患者的影响:大流行后期的见解
在PubMed上查看摘要
概括
此摘要是机器生成的。血液性恶性瘤患者面临高COVID-19死亡风险,即使接种了疫苗. 虽然严重感染和死亡率随着时间的推移而下降,但这些患者在SARS-CoV-2流行阶段仍然很脆弱.
科学领域
- 血液学
- 传染性疾病
- 癌症学
背景情况
- COVID-19 显著增加了血液恶性瘤患者的死亡风险.
- 血液性恶性瘤包括多发性骨髓瘤 (MM),慢性淋巴细胞白血病 (CLL) 和非霍奇金淋巴瘤 (NHL).
研究的目的
- 在疫情晚期疫苗接种的血液恶性瘤患者中确定COVID-19结果的危险因素.
- 评估疫苗接种对高危人群的COVID-19结果的影响.
主要方法
- 进行了一项单中心观察性研究.
- 这些数据是在大流行后期 (2022-2023) 收集的.
- 专注于被诊断患有血液性恶性瘤和COVID-19的接种疫苗的患者.
主要成果
- 分析了85例COVID-19病例,其中MM,CLL和NHL是普遍存在的.
- 尽管疫苗接种率很高 (97.6%),但23.5%的人患有严重/危急疾病.
- 整体和30天死亡率分别为22. 4%和11. 8%.
- 随着时间的推移,死亡率有所下降,但严重感染病例的死亡率并没有下降.
结论
- 患有血液性恶性瘤的患者面临来自SARS-CoV-2感染的持续高风险.
- 即使危急感染和死亡率随着时间的推移而降低,该群体在流行阶段仍然很脆弱.
相关概念视频
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

